FDA approves Novo Nordisk’s Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Novo Nordisk’s Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
Where Today's News Shapes Tomorrow
